InspireMD appoints Raymond W. Cohen to board of directors

InspireMD Inc. (NASDAQ: NSPR) announced the appointment of Raymond W. Cohen to its board of directors. The company develops the CGuard Prime carotid stent system for stroke prevention.

Cohen brings over 40 years of medical technology leadership experience. He served as CEO and co-founder of Axonics Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Until May 2025, Cohen served as chairman of SoniVie Ltd., a clinical stage company focused on hypertension device treatment, which Boston Scientific acquired for $600 million.

Cohen currently serves as an independent director for Kestra Medical (NASDAQ: KMTS) and PE-backed Spectrum Vascular Inc. He also serves as chairman of privately held Nalu Medical and vice chairman of privately held Tulavi Inc.

Previously, Cohen was CEO of Vessix Vascular Inc. and publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators that was later acquired by Zoll Medical. His work has earned him recognition including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio.

"We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, CEO of InspireMD. "His operational acumen, strategic vision, and experience driving transformative growth brings a unique perspective that will strengthen our execution and sharpen our long-term value-creation strategy."

InspireMD recently received PMA approval for its CGuard Prime carotid stent system and has shifted focus to commercial launch. The company utilizes its proprietary MicroNet mesh technology for carotid stenting procedures.

You May Also Be Interested In

• YZi Labs ends proxy fight with CEA Industries in board deal
• Provident Bank names Adriano Duarte as CFO, effective July 1
• Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board